In addition, the occurrence of gene mutations like CREBBP and EP300 mutations during disease course may predict worse overall survival (OS) and progression-free survival (PFS) for germinal center B cell-like DLBCL (9). This evidence concerns the gene CREBBP and diffuse large B-cell lymphoma.